
Protecting healthcare workers during Ebola outbreaks is an urgent public health responsibility. Vaccination can contribute to that protection, but an institutional recommendation can become difficu...
Objectives To describe the characteristics and outcomes of adults hospitalised with varicella in Belgium, where universal varicella vaccination is not offered in children and to identify implications for targeted vaccination strategies. Methods A retrospective study was conducted in three Belgian hospitals during a 10-year period (2012-2022), including adults hospitalised >24 h with varicella or varicella pneumonia, identified through microbiological results and minimal clinical datasets. Demographic, clinical, and outcome data were analysed. Results Among 74 hospitalised adults, 13 (17.6%) had varicella pneumonia. Most patients were male migrants living in precarious conditions, and a substantial proportion were undocumented. Pregnant women accounted for a quarter of admissions, and many reported recent contacts with a child with varicella. Most patients received antiviral therapy and had favourable outcomes; one death occurred in an immunocompromised patient. A notable fraction of cases would have been missed by routine surveillance relying on minimal clinical data alone. Conclusions In the three studied hospitals, adult hospitalisations caused by varicella cluster in socially vulnerable groups and pregnant women. Varicella vaccination for newly arrived refugees and systematic identification and vaccination of seronegative women of childbearing age could reduce the burden of varicella hospitalisations.
Background Pneumocystis jirovecii pneumonia (PJP) is an opportunistic infection which primarily affects immunocompromised individuals. The recommended dose of co-trimoxazole for treatment of PJP is 15–20 mg/kg/day of the trimethoprim component based on an underpowered 1975 study in 20 children with cancer. While this dose is effective, a lower dose may be sufficient and cause less toxicity.Method We conducted a retrospective cohort study of patients treated for ‘proven’ or ‘probable’ PJP at Christchurch Public Hospital, New Zealand between January 2018 and November 2023. We compared treatment limiting adverse drug reactions (ADR) and 30-day all-cause mortality in patients initiated on a conventional dose of co-trimoxazole (≥12.5 mg/kg/day) versus those initiated on a low dose of co-trimoxazole (<12.5 mg/kg/day).Results A total of 148 patients with a positive Pneumocystis jirovecii PCR or immunofluorescence result were treated with co-trimoxazole of whom 139 were categorised as having ‘proven’ or ‘probable’ PJP (36 low-dose (25.9%), 103 conventional-dose (74.1%)). A higher proportion of patients receiving conventional-dose co-trimoxazole required a treatment alteration due to an ADR (43.7%, 45/103) than patients receiving low-dose co-trimoxazole (16.7%, 6/36). There was no statistically significant difference in 30-day all-cause mortality between the low- and conventional-dose groups (adjusted hazard ratio for low- versus conventional-dose = 0.76, 95% confidence interval 0.29–1.98, p = 0.57).Conclusions In this comparatively large retrospective cohort, low-dose co-trimoxazole was associated with fewer treatment-limiting ADRs without an observed increase in mortality. These findings add to the growing body of observational evidence supporting the use of lower co-trimoxazole doses for the treatment of PJP.